PMID- 28485171
OWN - NLM
STAT- MEDLINE
DCOM- 20190425
LR  - 20190425
IS  - 0028-2685 (Print)
IS  - 0028-2685 (Linking)
VI  - 64
IP  - 4
DP  - 2017
TI  - BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal 
      melanoma.
PG  - 626-632
LID - 10.4149/neo_2017_419 [doi]
AB  - BRAF inhibitors substantially have impressive clinical efficacy in cutaneous 
      melanoma. However, their role in acral and mucosal melanoma remains unclear. 
      Records were reviewed of patients with metastatic or unresectable BRAF-mutant 
      acral and mucosal melanoma hospitalized and administrated BRAF inhibitors during 
      January 2011 and March 2016. Clinical data were collected to determine PFS, ORR, 
      DCR, OS, and safety. Among 28 acral and 12 mucosal melanoma patients treated with 
      BRAF inhibitors, median PFS were 3.6 (95%CI 3.0-6.4) and 4.4 (95%CI 0.8-12.7) 
      months, median OS were 6.2 (95%CI 6.1-12.1) and 8.2 (95%CI 6.6-19.9) months; ORRs 
      were 38.1% and 20.0%, DCRs were 81.0% and 70.0% in acral and mucosal melanoma, 
      respectively. BRAF inhibitors were well tolerated. The most common adverse 
      effects (AEs) were cutaneous and hematological. Grade 3/4 AEs were relatively 
      rare. In conclusion, BRAF inhibitors have acceptable efficacy and good tolerance 
      in BRAF mutant acral and mucosal melanoma.
FAU - Bai, X
AU  - Bai X
FAU - Mao, L L
AU  - Mao LL
FAU - Chi, Z H
AU  - Chi ZH
FAU - Sheng, X N
AU  - Sheng XN
FAU - Cui, C L
AU  - Cui CL
FAU - Kong, Y
AU  - Kong Y
FAU - Dai, J
AU  - Dai J
FAU - Wang, X
AU  - Wang X
FAU - Li, S M
AU  - Li SM
FAU - Tang, B X
AU  - Tang BX
FAU - Lian, B
AU  - Lian B
FAU - Zhou, L
AU  - Zhou L
FAU - Yan, X Q
AU  - Yan XQ
FAU - Guo, J
AU  - Guo J
FAU - Si, L
AU  - Si L
LA  - eng
PT  - Journal Article
PL  - Slovakia
TA  - Neoplasma
JT  - Neoplasma
JID - 0377266
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.11.1 (BRAF protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
SB  - IM
MH  - Humans
MH  - Melanoma/*drug therapy
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Proto-Oncogene Proteins B-raf/*antagonists & inhibitors
MH  - Retrospective Studies
MH  - Skin Neoplasms/*drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - BRAF inhibitor
OT  - acral
OT  - mucosal melanoma.
EDAT- 2017/05/10 06:00
MHDA- 2019/04/26 06:00
CRDT- 2017/05/10 06:00
PHST- 2017/05/10 06:00 [pubmed]
PHST- 2019/04/26 06:00 [medline]
PHST- 2017/05/10 06:00 [entrez]
AID - 10.4149/neo_2017_419 [doi]
PST - ppublish
SO  - Neoplasma. 2017;64(4):626-632. doi: 10.4149/neo_2017_419.